FDA approval of Zepbound was based on results from the phase 3 SURMOUNT-1 (adults with obesity or overweight and without type 2 diabetes) and SURMOUNT-2 (adults with obesity or overweight and with type 2 diabetes) trials which both demonstrated a statistically significant reduction in body weight compared to those who received placebo after 72 weeks of treatment
Potential Side Effects and Safety Considerations While most side effects are mild, some serious risks require attention
Everyone is different and the more your doctor knows about you, the better they can help you on your weight loss journey
A patient with coverage paying $25 monthly spends $450 over 18 months
First, our analysis does not account for confounding factors such as genetic variability, lifestyle influences, and other comorbidities or concurrent DMTs, which may affect AD risk and treatment response in DM2
Telehealth legitimacy reinforced